This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Diabetes Kidney Disease Research 
Cardiovascular Diabetology
AUGUST 23, 2024
Diabetic kidney disease (DKD) is associated with a higher risk of cardiovascular disease (CVD). Pentoxifylline (PTF), a nonselective phosphodiesterase inhibitor with anti-inflammatory, antiproliferative, and a.
129 
Medical Xpress - Cardiology
FEBRUARY 14, 2025
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients, according to results from an international clinical trial led by a Mount Sinai researcher.
139 
Science Daily - Heart Disease
JULY 8, 2024
New research shows combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to offer additional protection against heart and kidney disease in patients with diabetes.
125 
Cardiovascular Diabetology
MAY 2, 2024
Insulin resistance and chronic kidney disease are both associated with increased coronary artery disease risk. Many formulae estimating glucose disposal rate in type 1 diabetes infer insulin sensitivity from c.
Cardiovascular Diabetology
FEBRUARY 14, 2025
People living with diabetes mellitus (DM) and chronic kidney disease (CKD) are at significantly high risk of cardiovascular events (CVEs), however the predictive performance of traditional risk prediction meth.
Cardiovascular Diabetology
MARCH 21, 2025
Mineralocorticoid receptor antagonists (MRAs) are often underutilized in patients with heart failure (HF), particularly those with diabetes and/or chronic kidney disease (CKD). However, the impact of concurren.
Science Daily - Heart Disease
FEBRUARY 14, 2025
New research shows sotagliflozin is the only drug in its class to demonstrate these results.
111 
Cardiovascular Diabetology
APRIL 24, 2024
This study was designed to assess the associations between emerging cardiometabolic indices—the atherogenic index of plasma (AIP), the stress hyperglycemia ratio (SHR), the triglyceride-glucose (TyG) index, an.
Cardiovascular Diabetology
JANUARY 8, 2024
Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes.
CardiacWire
MAY 8, 2024
A new JAMA study revealed that a shocking 90% of US adults are at risk of developing cardiovascular-kidney-metabolic (CKM) syndrome, underscoring the need for preventative action before we face a wave of CKM-related heart disease. Stage 4 (heart disease, with or without kidney disease) – 9.2% in Whites).
116 
Cardiovascular Diabetology
MARCH 27, 2025
Cardiovascular Autonomic Neuropathy (CAN) is one of the most devastating complications of Diabetes Mellitus (DM) and presents high morbidity and mortality. Its association with diabetic kidney disease (DKD) wo.
Cardiovascular Diabetology
AUGUST 6, 2024
Objective To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronary artery disease (CAD). Research design and methods All patients with diabetes and CAD undergoing a coronary angiography between 2010 and 2021 according to the Swedish Angiography and Angioplasty Registry were included.
Cardiovascular Diabetology
OCTOBER 8, 2024
Most existing risk equations for predicting/stratifying individual diabetic kidney disease (DKD) risks were developed using relatively dated data from selective and homogeneous trial populations comprising pre.
Cardiovascular Diabetology
JUNE 14, 2024
Diabetic kidney disease is an established risk factor for heart failure. However, the impact of incident heart failure on the subsequent risk of renal failure has not been systematically assessed in diabetic p.
HCPLive
OCTOBER 25, 2024
New research indicates semaglutide reduced albuminuria and body weight in CKD patients without diabetes, highlighting its potential renal benefits.
Cardiovascular Diabetology
APRIL 9, 2024
Hypertension and chronic kidney disease (CKD) pose significant public health challenges, sharing intertwined pathophysiological mechanisms. Prediabetes is recognized as a precursor to diabetes and is often acc.
Cardiovascular Diabetology
JULY 3, 2024
Despite improved glycemic treatment, the impact of glycation on pathological consequences may persist and contribute to adverse clinical outcomes in diabetes. In the present study we.
64 
Cardiovascular Diabetology
JANUARY 2, 2024
The triglyceride-glucose (TyG) index is a reliable surrogate marker of insulin resistance and previous studies have confirmed the association of TyG index with incident chronic kidney disease (CKD). However, t.
Cardiovascular Diabetology
DECEMBER 12, 2023
In the last years, the classical pattern of diabetic kidney disease (DKD) has been partially overcome, because of the uncovering of a new DKD phenotype with significant renal dysfunction without presence of al.
Cardiovascular Diabetology
OCTOBER 23, 2024
A Chronic Kidney Disease (CKD) Epidemiology Collaboration (EPI) formula not including a Black race coefficient has been recently developed and is now recommended in the US. The new (2021) equation was shown to.
Cardiovascular Diabetology
FEBRUARY 27, 2025
Selecting the optimal first-line therapy for type 2 diabetes is essential for achieving glycemic control and providing cardio-renal protection, though the combined benefits of metformin with SGLT2 inhibitors,
52 
Circulation
MARCH 9, 2025
Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidney disease, or heart failure, as well as among adults with few cardiovascular risk factors. Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025.
Journal of Clinical Investigation - Cardiology
SEPTEMBER 17, 2024
BACKGROUND Teplizumab, a non-FcR-binding anti-CD3 mAb, is approved to delay progression of type 1 diabetes (T1D) in at-risk patients. IL7R expression was reduced, and patients with lower expression of CD127 had longer diabetes-free intervals.
52 
Cardiometabolic Health Congress
JUNE 24, 2024
As a leader in the field of research-based cardiometabolic health education, CMHC is proud to present its CME education outcomes study at ADA (American Diabetes Association) 2024 Scientific Sessions, which offers its education-focused agenda to a wide number of healthcare practitioners from all areas of the U.S.
52 
Cardiometabolic Health Congress
AUGUST 14, 2024
Themed “Decoding the Constellation of Cardiometabolic Health and Risk Factors,” this year’s congress will tackle the growing health threat posed by cardiometabolic diseases, affecting 47 million people in the US. Aronne, MD Expert Perspectives on Initiating and Maintaining Insulin Therapy in Type 2 Diabetes Patients Jay H.
72 
European Journal of Heart Failure
NOVEMBER 26, 2024
1.34), ischaemic heart disease (HR 1.20, 95% CI 1.09–1.31), 1.29), diabetes mellitus (HR 1.15, 95% CI 1.04–1.27) Baseline characteristics independently associated with discontinuation were: estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m m 2 (hazard ratio [HR] 1.75, 95% confidence interval [CI] 1.34–2.27),
Cardiometabolic Health Congress
NOVEMBER 8, 2023
2023, the American Heart Association (AHA) issued a presidential advisory on the urgency of this systemic disorder involving heart disease, kidney disease, diabetes and obesity. based, multidisciplinary conference addressing cardiometabolic disease prevention, management, and treatment.
Cardiometabolic Health Congress
OCTOBER 26, 2023
In response, the NAFLD Nomenclature Initiative was formed in 2020 and tasked to determine if new international medical language could help aid research funding, reduce stigmatization, and better represent the pathophysiology of liver disease related to metabolic dysfunction. Nonalcoholic fatty liver disease (NAFLD) & NASH.
52 
Cardiometabolic Health Congress
JULY 12, 2023
“In addition to our new online hubs, we are continually designing live education for delivery as satellite symposia at other large conferences such as the American Heart Association or American Diabetes Association Scientific Sessions. ” Learners can see some of the CMHC experts in person on Aug.
40 
Cardiometabolic Health Congress
OCTOBER 10, 2024
Vitadio : Digital therapeutics for type 2 diabetes and prediabetes, expanding globally. LumineticsCore : An AI diagnostics company with FDA-cleared systems for detecting diabetic retinopathy. Eko : AI-powered heart sound and EKG sensors paired with FDA-approved software for heart disease monitoring.
52 
Stroke Journal
JANUARY 30, 2025
Hypertension, diabetes, hyperlipidemia, and chronic kidney disease are well-known cardiovascular risk factors for ICH. These findings support further research into whether polygenic profiling can improve clinical decision-making in AF patients. Stroke, Volume 56, Issue Suppl_1 , Page A49-A49, February 1, 2025.
European Journal of Heart Failure
NOVEMBER 23, 2023
Abstract Aims Transthyretin cardiac amyloidosis (ATTR-CA) is an infiltrative cardiomyopathy that commonly presents with concomitant chronic kidney disease. In a subgroup of patients (n = 349) without concomitant hypertension, diabetes mellitus or chronic kidney disease, albuminuria was also associated with mortality (HR=2.98, 95%CI[1.72-5.17],
Circulation
NOVEMBER 11, 2024
The secondary outcomes comprise the odds of adverse events, including myocardial infarction, ischemic stroke, transient ischemic attack (TIA), occlusive atherosclerotic disease, percutaneous coronary intervention, and coronary artery bypass graft (CABG)., The hemophilia cohort was slightly older (63.2[16.8]
40 Circulation: Heart Failure
MARCH 8, 2024
The prevalence of HF risk factors was high: hypertension, 61.9%; former or current smoking, 53.7%; obesity 34.8%; diabetes; 24.7%; and chronic kidney disease; 22%. Overt cardiovascular disease, which ranged from 2.1% (HF) to 13.6% (atrial fibrillation), was less common. were female, 25.6% were Black, 12.8% were White.
Circulation
NOVEMBER 11, 2024
Evaluate the benefit in important cardiovascular outcomes and safety in elderly patients of a blood pressure control ≤ 130mmHg compared to standard of care.Methods:The research was performed in PubMed, EMBASE, Scielo, LILACS, and Cochrane Central Register of Controlled Trials (CENTRAL) from January 1st, 2013 to May 1st, 2023.
European Journal of Heart Failure
MARCH 4, 2024
Prior studies were able to show that sodium–glucose cotransporter 2 inhibitors may reduce the incidence of LRTI in patients with type 2 diabetes. Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. Patients who developed LRTI had a 2.7-fold
Stroke Journal
JANUARY 30, 2025
Propensity score-matched analysis (PSM) (1:1) was performed with matching for age, gender, race, BMI, hypertension, diabetes mellitus, chronic kidney disease, hemoglobin level, low-density lipid (LDL) level, left ventricular ejection fraction, and various drugs including ACEi, ARBi, ARNI, beta-blockers, and diuretics.
40 Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
Risk factors such as smoking, chronic kidney disease, and aging can contribute to plaque formation. The gradual loss of elasticity in arterial walls and the presence of other risk factors, such as high blood pressure and diabetes, contribute to the increased risk of cardiovascular disease (CVD) observed in aging populations.
40 
DAIC
MARCH 25, 2025
25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies." Additional ACC.25
DAIC
MARCH 25, 2025
25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies." Additional ACC.25
European Journal of Heart Failure
JANUARY 17, 2025
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: a FIDELITY analysis. a If patients were receiving both types of diuretics at baseline, they were included in both subgroups.
Open Heart
JULY 6, 2023
Background Chronic kidney disease (CKD) and atrial fibrillation (AF) are increasing in prevalence globally and share common risk factors. Age, sex, diabetes, hypertension and heart failure were chosen as variables of interest. Methods PubMed, EMBASE and CINAHL were searched from inception to June 2022.
DAIC
SEPTEMBER 11, 2024
11, 2024 — In the first national estimate in two decades, researchers at the University of California-San Francisco (UCSF) report that 10.5 A-Fib, as the condition is commonly known, has been on the rise for at least the past decade, driven by the aging of the population, along with increasing rates of hypertension, diabetes and obesity.
Cardiometabolic Health Congress
AUGUST 8, 2024
Cardiometabolic risk encompasses a complex spectrum of interrelated conditions, including cardiovascular disease, type 2 diabetes, and metabolic syndrome. Key contributions: Advanced cardiac imaging (e.g., high-sensitivity troponin, NT-proBNP) in risk stratification Utilization of advanced echocardiographic techniques (e.g.,
59
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content